계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Gemmus Pharma
company
About
Gemmus develops innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $3.30M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$5.10M
Gemmus Pharma has raised a total of
$5.10M
in funding over 2 rounds. Their latest funding was raised on
May 13, 2014 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 13, 2014 | Series B | $3.30M | 1 | — | — | Detail |
| Jun 28, 2012 | Series A | $1.80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Gemmus Pharma is funded by 1 investors.
Wilmington Investor Network
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Wilmington Investor Network
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
